tbuckley/cabot-search huggingface dataset:
Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin–Producing <i>Escherichia coli</i>
Authors: Silviu Grisaru, Jianling Xie, Susan Samuel, Lisa Hartling, Phillip I. Tarr, David Schnadower, Stephen B. Freedman
Journal: JAMA Pediatrics (2016)

The associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli (STEC) remain unclear.To determine the relationship between hydration status, the development and severity of hemolytic uremic syndrome (HUS), and adverse outcomes in STEC-infected individuals.MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials via the OvidSP platform, PubMed via the National Library of Medicine, CINAHL Plus with full text, Scopus, Web of Science, ClinicalTrials.gov, reference lists, and gray literature were systematically searched.Two reviewers independently identified studies that included patients with hydration status documentation, proven or presumed STEC infection, and some form of HUS that developed. No language restrictions were applied.Two reviewers independently extracted individual study data, including study characteristics, population, and outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale; strength of evidence was adjudicated using the Grading of Recommendations Assessment, Development, and Evaluation method. Meta-analyses were conducted using random-effects models.Development of HUS, complications (ie, oligoanuric renal failure, involvement of the central nervous system, or death), and interventions (ie, renal replacement therapy).Eight studies comprising 1511 patients (all children) met eligibility criteria. Unpublished data were provided by the authors of 7 published reports. The median risk-of-bias score was 7.5 (range, 6-9). No studies evaluated the effect of hydration during STEC infections on the risk for HUS. A hematocrit value greater than 23% as a measure of hydration status at presentation with HUS was associated with the development of oligoanuric HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90]; I2 = 17%), and death (OR, 5.13 [95% CI, 1.50-17.57]; I2 = 55%). Compared with putatively hydrated patients, clinically dehydrated patients had an OR of death of 3.71 (95% CI, 1.25-11.03; I2 = 0%). Intravenous fluid administration up to the day of HUS diagnosis was associated with a decreased risk of renal replacement therapy (OR, 0.26 [95% CI, 0.11-0.60]).Two predictors of poor outcomes for STEC-infected children were identified: (1) the lack of intravenous fluid administration prior to establishment of HUS and (2) a higher hematocrit value at presentation. These findings point to an association between dehydration and adverse outcomes for children with HUS.
Association Between the Amount of Vaginal Mesh Used With Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence
Authors: Bilal Chughtai, Matthew D. Barber, Jialin Mao, James C. Forde, Sharon-Lise T. Normand, Art Sedrakyan
Journal: JAMA Surgery (2016)

Mesh, a synthetic graft, has been used in pelvic organ prolapse (POP) repair and stress urinary incontinence (SUI) to augment and strengthen weakened tissue. Polypropylene mesh has come under scrutiny by the US Food and Drug Administration.To examine the rates of mesh complications and invasive reintervention after the placement of vaginal mesh for POP repair or SUI surgery.This investigation was an observational cohort study at inpatient and ambulatory surgery settings in New York State. Participants were women who underwent transvaginal repair for POP or SUI with mesh between January 1, 2008, and December 31, 2012, and were followed up through December 31, 2013. They were divided into the following 4 groups based on the amount of mesh exposure: transvaginal POP repair surgery with mesh and concurrent sling use (vaginal mesh plus sling group), transvaginal POP repair with mesh and no concurrent sling use (vaginal mesh group), transvaginal POP repair without mesh but concurrent sling use for SUI (POP sling group), and sling for SUI alone (SUI sling group).The primary outcome was the occurrence of mesh complications and repeated invasive intervention within 1 year after the initial mesh implantation. A time-to-event analysis was performed to examine the occurrence of mesh erosions and subsequent reintervention. Secondary analyses of an age association (<65 vs ≥65 years) were conducted.The study identified 41 604 women who underwent 1 of the 4 procedures. The mean (SD) age of women at their initial mesh implantation was 56.2 (13.0) years. The highest risk of erosions was found in the vaginal mesh plus sling group (2.72%; 95% CI, 2.31%-3.21%) and the lowest in the SUI sling group (1.57%; 95% CI, 1.41%-1.74%). The risk of repeated surgery with concomitant erosion diagnosis was also the highest in the vaginal mesh plus sling group (2.13%; 95% CI, 1.76%-2.56%) and the lowest in the SUI sling group (1.16%; 95% CI, 1.03%-1.31%).The combined use of POP mesh and SUI mesh sling was associated with the highest erosion and repeated intervention risk, while mesh sling alone had the lowest erosion and repeated intervention risk. There is evidence for a dose-response relationship between the amount of mesh used and subsequent mesh erosions, complications, and invasive repeated intervention.
Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia.
Authors: Christian P Pallasch, Michaela Patz, Yoon Jung Park, Susanne Hagist, Daniela Eggle, Rainer Claus, Svenja Debey-Pascher, Alexandra Schulz, Lukas P Frenzel, Julia Claasen, Nadine Kutsch, Günter Krause, Christine Mayr, Andreas Rosenwald, Christoph Plass, Joachim L Schultze, Michael Hallek, Clemens-Martin Wendtner
Journal: Blood (2009)
Selective Depletion of Alloreactive T Cells and Study of Anti-Tumor Activity of Specific T Cell Clones in Patients with Leukemia and Renal Carcinoma.
Authors: Eva Matejkova, Ivana Buresova, Petra Vidlakova, Drahomira Kyjovska, Ellen S. Vitetta, Jaroslav Michalek
Journal: Blood (2007)
Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies.
Authors: Donatella Baronciani, Alessandro Rambaldi, Federica Pilo, Caterina Mico, Simona Deplano, Cristina Depau, Paolo Dessalvi, Emanuele Angelucci
Journal: Blood (2006)
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Authors: Jared R. Lowe, Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss, Brent A. Hanks
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the clinic. We are currently unable to predict which patients will develop more severe toxicities associated with these treatment regimens. <h3>Case presentation</h3> We present a patient with stage IV melanoma that developed rapid onset autoimmune type 1 diabetes (T1D) in response to combination ipilimumab and nivolumab immunotherapy. At the time of the patient's presentation with diabetes ketoacidosis, a confirmed anti-GAD antibody seroconversion was noted. Longer-term follow-up of this patient has demonstrated a durable complete response based on PET CT imaging along with a persistently undetectable C-peptide level. Single nucleotide polymorphism gene sequencing and HLA risk allele analysis has revealed the patient to lack any established genetic predisposition to the development of autoimmune T1D. <h3>Conclusions</h3> While larger studies are necessary to better understand the role of genetic risk factors for the development of autoimmune toxicities in those patients undergoing checkpoint inhibitor immunotherapy, these results suggest that pre-screening patients for known T1D risk alleles may not be indicated. Additional investigation is needed to determine whether an approach such as T cell receptor clonotypic analysis to identify the presence of autoreactive T cell clones may be an effective approach for predicting which patients are at risk for the development of autoinflammatory toxicities while undergoing checkpoint inhibitor immunotherapy.
Electronic fetal monitoring, cerebral palsy, and caesarean section: assumptions versus evidence
Authors: Karin B Nelson, Thomas P Sartwelle, Dwight J Rouse
Journal: BMJ (2016)

Given evidence that cerebral palsy is not reduced by electronic fetal monitoring, <b>Karin Nelson</b>, <b>Thomas Sartwelle</b>, and <b>Dwight Rouse</b> ask why routine monitoring and related litigation continue to contribute to high rates of caesarean births
Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models
Authors: Janine C. Deddens, Amir Hossein Sadeghi, Jesper Hjortnaes, Linda W. van Laake, Marc Buijsrogge, Pieter A. Doevendans, Ali Khademhosseini, Joost P. G. Sluijter
Journal: Advanced Healthcare Materials (2016)

Cardiac remodeling is critical for effective tissue healing, however, excessive production and deposition of extracellular matrix components contribute to scarring and failing of the heart. Despite the fact that novel therapies have emerged, there are still no lifelong solutions for this problem. An urgent need exists to improve the understanding of adverse cardiac remodeling in order to develop new therapeutic interventions that will prevent, reverse, or regenerate the fibrotic changes in the failing heart. With recent advances in both disease biology and cardiac tissue engineering, the translation of fundamental laboratory research toward the treatment of chronic heart failure patients becomes a more realistic option. Here, the current understanding of cardiac fibrosis and the great potential of tissue engineering are presented. Approaches using hydrogel‐based tissue engineered heart constructs are discussed to contemplate key challenges for modeling tissue engineered cardiac fibrosis and to provide a future outlook for preclinical and clinical applications.
Results of a Phase 2 Trial with Valproic Acid Alone or in Combination with All-Trans-Retinoic Acid (ATRA) in 29 Patients with Myelodysplastic Syndromes.
Authors: Kuendgen Andrea, Strupp Corinna, Hildebrandt Barbara, Knipp Sabine, Junge Baerbel, Haas Rainer, Germing Ulrich, Gattermann Norbert
Journal: Blood (2004)
Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens
Authors: Riikka Uotila, Anna Kaarina Kukkonen, Dario Greco, Anna Susanna Pelkonen, Mika Juhani Mäkelä
Journal: Journal of Allergy and Clinical Immunology (2016)
Evaluation of the In Vitro Activity of the Multikinase Inhibitor BAY 43-9006 (Sorafenib) in Primary Cells from Patients with Myelofibrosis with Myeloid Metaplasia (MMM).
Authors: Joseph W. Smith, Heather Powell, Ayalew Tefferi, Scott H. Kaufmann, Terra Lasho, David Loegerling, Marina Galvez, Ruben Mesa
Journal: Blood (2005)
First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Yvonne A. Efebera, Ashley E Rosko, Craig Hofmeister, Joe Benner, Courtney Bakan, Kathleen Stamper, Tammy Lamb, Devine Hollie, Megan Sell, David Avigan, Don M Benson
Journal: Blood (2015)
High Frequency of Loss of Heterozygosity Due to Uniparental Disomy or Allele Deletion of Ocular Adnexal MALT-Type Lymphoma.
Authors: Yoshitaka Asakura, Seishi Ogawa, Motohiro Kato, Go Yamamoto, Akiko Maeshima, Yoshihiro Matsuno, Shigenobu Suzuki, Akihiro Kaneko, Junko Nomoto, Kazuki Tanimoto, Naohiro Sekiguchi, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Kensei Tobinai, Yukio Kobayashi
Journal: Blood (2007)
Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.
Authors: Veena Charu, Victor Moyo, Donghan Luo, Francois E. Wilhelm
Journal: Blood (2007)
A Higher Ratio of Dose to Actual Weight of Conditioning Chemotherapy Leads to More Toxicity without Improvement in Outcome in Autologous HSC Transplant for DLBCL.
Authors: Luciano J. Costa, Ivana N. Micallef, David J. Inward, Patrick B. Johnston, Luis F. Porrata, Mark R. Litzow, Stephen M. Ansell
Journal: Blood (2007)
Fertility authority must provide evidence for tests and treatments, say researchers
Authors: Jacqui Wise
Journal: BMJ (2016)

Many UK fertility clinics make claims on their websites about the benefits of treatments without providing good quality supporting evidence, concludes research published in the online journal BMJ Open .1

A linked Analysis article in The BMJ finds that most fertility treatments offered outside standard in vitro fertilisation (IVF) treatment are not supported by good evidence.2 The findings will be part of a Panorama investigation broadcast on Monday 28 November on BBC One.

Carl Heneghan, from the Centre for Evidence Based Medicine at Oxford University, who is the lead author of both papers, has called on the UK Human Fertilisation and Embryology Authority (HFEA) to provide a central resource of continually updated evidence so that patients can make informed choices about tests and treatments.

Around a seventh of UK couples have problems conceiving. Fertility services are offered by more than 200 NHS and private clinics registered with the HFEA. These clinics offer a range of investigations and treatments, …
Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies
Authors: William G. Rice, Jeff Lightfoot, Hongying Zhang, Tiffany Cheng, Avanish Vellanki, Robert Peralta, Stephen B Howell, Andrea Local, Fannie Chau, Luis Esquivies
Journal: Blood (2015)
Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML
Authors: Domenico Russo, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, Simona Soverini, Ilaria Iacobucci, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti
Journal: Blood (2014)
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
Authors: L Kazianka, C Drucker, C Skrabs, W Thomas, T Melchardt, S Struve, M Bergmann, P B Staber, E Porpaczy, C Einberger, M Heinz, A Hauswirth, M Raderer, I Pabinger, R Thalhammer, A Egle, C-M Wendtner, G Follows, G Hoermann, P Quehenberger, B Jilma, U Jaeger
Journal: Leukemia (2016)

Bleeding because of impaired platelet function is a major side effect of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation (RIPA) in 64 patients with chronic lymphocytic leukemia (CLL) under ibrutinib at 287 time points. Eighty-seven bleeding episodes in 39 patients were registered (85 Common Toxicity Criteria (CTC) grade 1 or 2, 2 CTC grade 3) during a median observation period of 10.9 months. At times of bleeding, RIPA values were significantly lower (14 vs 28 U; P<0.0001). RIPA was impaired in patients receiving concomitant antiplatelet therapy or anticoagulation (14 vs 25 U, P=0.005). A gradual decline of median RIPA values was observed with increasing bleeding severity. Importantly, no CTC grade 2 or 3 bleeding were observed with RIPA values of >36 U. Sequential monitoring indicated a decrease of RIPA values from a median of 17 to 9 U within 2 weeks after initiation of treatment as well as an increase above the critical threshold of 36 U within 7 days when ibrutinib was paused. Low RIPA values were similar during treatment with another BTK inhibitor, CC292. Quantitative assessment of platelet function is a practical tool to monitor bleeding tendency under BTK-inhibitor therapy.
High-Throughput Nanomechanical Platelet Contraction Measurements Using Patterned Hydrogels.
Authors: David R Myers, Ashley C Brown, Yongzhi Qiu, Yumiko Sakurai, Reginald Tran, Byungwook Ahn, Robert Mannino, Todd Sulchek, Andew Lyon, Thomas H Barker, Wilbur Lam
Journal: Blood (2012)
CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.
Authors: Yu-Tzu Tai, Giovanni Tonon, Merav Leiba, Xian-Feng Li, Peter Burger, Weihua Song, Klaus Podar, Dharminder Chauhan, Nihkil Munshi, Kenneth C. Anderson
Journal: Blood (2007)
Prolonged Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Its Association with an Increase in CD8+ CX3CR1+ Cells in Bone Marrow.
Authors: Xiao-hui Zhang, Guo-xiang Wang, Yan-rong Liu, Lan-Ping Xu, Kai-Yan Liu, Wei Han, Yu Wang, Hai-xia Fu, Meng Lv, Min Wang, Yi Zhou, Xiao-Jun Huang
Journal: Blood (2012)
Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer
Authors: Deepansh Dalela, Patrick Karabon, Firas Abdollah
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies.
Authors: Andrew J. Yee, Thomas R. Spitzer, Susan L. Saidman, Juanita Shaffer, Karen A. Power, Steven L. McAfee, Karen K. Ballen, Eyal C. Attar, Frederic I. Preffer, Megan Sykes, Bimalangshu R. Dey
Journal: Blood (2005)
Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
Authors: Van Hung Tran, Florence Persat, Sophie Gardes, Jeremy Monfray, Sophie Ducastelle-Leprêtre, Damien Dupont, Mohamad Sobh, Fiorenza Barraco, Hélène Labussière-Wallet, Xavier Thomas, Franck E. Nicolini, Caroline Lejeune, Marie Balsat, René Ecochard, Mauricette Michallet
Journal: Blood (2015)
Trump chooses Obamacare opponent to lead Health and Human Services
Authors: Michael McCarthy
Journal: BMJ (2016)

US President-elect Donald Trump has nominated Representative Tom Price, a conservative Republican from Georgia, to be his secretary of Health and Human Services (HHS). Price, 62, a former orthopedic surgeon, has sought to repeal or defund President Obama’s Affordable Care Act since its passage in 2010.

The nomination suggests that Trump intends to pursue his campaign pledge to repeal and replace the health reform law, as well as proceed with major overhauls of Medicaid, the state-federal insurance plan for people who are poor or have a disability, and Medicare, the federal insurance plan for elderly people, sought by Republican congressional leaders.

Price has also attempted to end federal …
The Activator of Transcription 3 (STAT3) Gene Polymorphisms Are Associated with Treatment Outcomes In Acute Myeloid Leukemia
Authors: Bao-An Chen, Yue-jiao Zhong, Ji-feng Feng, Lu Cheng, Yufeng Li, Jun Qian, Jian Cheng, Wen Bao, Jia-hua Ding
Journal: Blood (2010)
Prevention of Pulmonary Hypertension and Suppression of Pulmonary Inflammation and Platelet Activation by Breathing Nitric Oxide in Lambs Subjected to Hemorrhagic Shock and Autologous Stored Blood Transfusion
Authors: David M. Baron, Arkadi Beloiartsev, Akito Nakagawa, Christopher P. Stowell, Kenneth D. Bloch, Warren M. Zapol
Journal: Blood (2012)
Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups
Authors: Mark Reinwald, Daniel Nowak, Uwe Platzbecker, Aristoteles Giagounidis, Katharina S. Götze, Oliver G. Ottmann, Detlef Haase, Katayoon Shirneshan, Richard F Schlenk, Anne Letsch, Michael Lübbert, Arnold Ganser, Verena Nowak, Stephanie Fey, Julia Obländer, Maximilian Mossner, Ulrich Germing, Wolf-Karsten Hofmann, Florian Nolte
Journal: Blood (2012)
Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium
Authors: Gabriele Buda, Alessandro Martino, Daniele Campa, Juan Sainz, Rui Manuel Vieira Reis, Ramón García-Sanz, Krzysztof Jamroziak, Rafael Rios, Manuel Jurado, Zofia Szemraj-Rogucka, Herlander Marques, Victor Moreno, Fabienne Lesueur, Charles Dumontet, Federica Gemignani, Stefano Landi, Enrico Orciuolo, Anna Maria Rossi, Mario Petrini, Federico Canzian
Journal: Blood (2011)
Induction of Micro RNA-143 and 145 In Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After In Vitro exposure to Lenalidomide Correlates with Clinical Response In Patients Harboring the Del5q Abnormality
Authors: Christopher P. Venner, Alan F. List, Thomas J. Nevill, H. Joachim Deeg, Gisela Caceres, Bart Lee Scott, Lubomir Sokol, Sandy Sung, Aly Karsan
Journal: Blood (2010)
Fish Is the Best Method to Detect BCL2/IgH Translocation in Follicular Lymphoma at Diagnosis. A Comparative Study with Conventional Cytogenetics, Fish and PCR (Biomed-2 Primers) Techniques.
Authors: Blanca Espinet, Beatriz Bellosillo, Elisabet Gregori, Veronica Escurriol, Marta Salido, Lourdes Florensa, Carme Pedro, Carles Besses, Soledad Woessner, Sergi Serrano, Francesc Sole
Journal: Blood (2004)
Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.
Authors: Connie L. Erickson-Miller, Evelyn Delorme, Maya Iskander, Leslie Giampa, Christpher B. Hopson, Juan Luengo, Kevin Duffy, Susan B. Dillon, Jon Rosen, Stephen Miller, Peter Lamb, Shin-Shay Tian
Journal: Blood (2004)
Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of Saudi Patients From the Eastern Province
Authors: Abdulrahman Alsultan, Idowu Akinsheye, Nadia Solovieff, Hazem Ghabbour, Duyen A. Ngo, Daniel A Dworkis, Clinton T. Baldwin, Paola Sebastiani, Lindsay A. Farrer, Martin H. Steinberg, David H.K. Chui
Journal: Blood (2010)